Nitroglycerin
Nitroglycerin, sold for under-the-tongue use as Nitrostat, is a nitrate, a vasodilator (a medicine that widens blood vessels). The US label read, for Nitrostat sublingual tablets, lists the acute relief of an attack of angina pectoris, chest pain from coronary artery disease, and the acute prevention of an attack. The label says the principal action of nitroglycerin is relaxation of vascular smooth muscle. Other nitroglycerin products were not read.
Also called Nitrostat · Glyceryl trinitrate
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 4917 (synonym glyceryl trinitrate); UNII G59M7S0WS3. MeSH descriptor D005996 is Nitroglycerin. RxClass lists the FDA chemical class Nitrates and the established pharmacologic class Nitrate Vasodilator; the record is filed under the class page Nitrates on that evidence. The label read is the Viatris Specialty LLC label for Nitrostat, application NDA021134, effective 2023-02-15 in openFDA, the label the class page already uses. The plan row pointed at a generic label (ANDA089773); the single-ingredient brand label replaces it. Nitrostat labels from repackagers and other nitroglycerin products were not read. Statements are scoped to the sublingual tablet. This page records the label indication, the product form and the mechanism sentence only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says the principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle.
Claims and evidence
Context People with angina pectoris due to coronary artery disease, as described in the US label of Nitrostat sublingual tablets
- Recipient
- Recipient not specified
- Population
- Patients with angina pectoris due to coronary artery disease, for the acute relief or the acute prophylaxis of an attack, as the indications section of the label states. The label passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with angina pectoris due to coronary artery disease
- Excluded
- None stated
The US label of Nitrostat (nitroglycerin sublingual tablets, Viatris Specialty LLC, application NDA021134; the version dated 2023-02-15 in openFDA) describes the product as a stabilized sublingual compressed nitroglycerin tablet and a nitrate vasodilator. It lists the acute relief of an attack, or acute prophylaxis of an attack, of angina pectoris due to coronary artery disease.
Applies to Recipient not specified People with angina pectoris due to coronary artery disease, as described in the US label of Nitrostat sublingual tablets
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for the sublingual tablet only; other nitroglycerin products were not read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read.
- Retrieved
- Source effective date
- 2023-02-15
- Source state
- Current
- Version fingerprint
cae4d61c84fb7ab7ae29bb11fadbc657fd705f74cd61c6d6651902c24afdebbb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read.
- Retrieved
- Source effective date
- 2023-02-15
- Source state
- Current
- Version fingerprint
cae4d61c84fb7ab7ae29bb11fadbc657fd705f74cd61c6d6651902c24afdebbb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- Label passage quoted in the research quote table (NIT-LB-04, NIT-LB-05).
- Retrieved
- Source effective date
- 2023-02-15
- Source state
- Current
- Version fingerprint
cae4d61c84fb7ab7ae29bb11fadbc657fd705f74cd61c6d6651902c24afdebbb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].description[0]
- How it applies
- Label passage quoted in the research quote table (NIT-LB-06).
- Retrieved
- Source effective date
- 2023-02-15
- Source state
- Current
- Version fingerprint
cae4d61c84fb7ab7ae29bb11fadbc657fd705f74cd61c6d6651902c24afdebbb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists the acute relief and acute prophylaxis of an attack of angina pectoris due to coronary artery disease as the indication: Angina pectoris
Applies to Recipient not specified People with angina pectoris due to coronary artery disease, as described in the US label of Nitrostat sublingual tablets
The US label of Nitrostat (nitroglycerin sublingual tablets, Viatris Specialty LLC, application NDA021134; the version dated 2023-02-15 in openFDA) describes the product as a stabilized sublingual compressed nitroglycerin tablet and a nitrate vasodilator. It lists the acute relief of an attack, or acute prophylaxis of an attack, of angina pectoris due to coronary artery disease.Limitations. This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for the sublingual tablet only; other nitroglycerin products were not read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:nitroglycerin- Content hash
7542d7ab1aa64524d07335226cbe094f1e39b8230fbb720bfc09d349a45a1bf4